AstraZeneca's nirsevimab approved as RSV treatment for babies, infants
GOLFX/iStock via Getty Images         
The US FDA has approved AstraZeneca's Beyfortus (nirsevimab) to prevent respiratory syncytial virusÂ in babies and infants up to two years old.
The monoclonal antibody is to be given as a single dose before the RSV season begins in the fall.

Approval was based on the results of three trials.
According to the American Academy of Pediatrics, between 1% and 3% of children under 12 months in the US are hospitalized annually because of RSV.

More on AstraZeneca

AstraZeneca: What's Next? (Rating Downgrade)
AstraZeneca: Think Medium-To-Long Term